Immune Design Announces Launch of Web Portal for SYNOVATE Phase 3 Study of CMB305 Immunotherapy in Synovial Sarcoma
May 24, 2018 08:00 ET
|
Immune Design Corp.
-- 1st global Phase 3 trial focused on synovial sarcoma patients -- www.synovatestudy.com SEATTLE and SOUTH SAN FRANCISCO, Calif., May 24, 2018 (GLOBE NEWSWIRE) -- Immune...
Immune Design’s GLAAS™ Platform Shown to Modulate the Allergic Immune Response
March 04, 2016 08:00 ET
|
Immune Design Corp.
Establishes Potential for the Treatment of Pollen and Peanut Allergies Data Presented at American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting SEATTLE and SOUTH...
Immune Design to Report Fourth Quarter and Year End 2015 Financial Results
March 03, 2016 08:00 ET
|
Immune Design Corp.
SEATTLE and SOUTH SAN FRANCISCO, March 03, 2016 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on cancer, today announced that it will report fourth...
Immune Design to Present at Cowen and Company 36th Annual Health Care Conference
February 29, 2016 08:00 ET
|
Immune Design Corp.
SEATTLE and SOUTH SAN FRANCISCO, Calif., Feb. 29, 2016 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on oncology, today announced that Carlos Paya,...
Immune Design Announces Positive Topline Data From Three Phase 1 Clinical Trials of Immuno-oncology Product Candidates
February 09, 2016 08:00 ET
|
Immune Design Corp.
SEATTLE and SOUTH SAN FRANCISCO, Calif., Feb. 09, 2016 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on oncology, today reported positive topline...
Immune Design Receives Orphan Drug Designation From the U.S. FDA for Complementary Components of CMB305
January 08, 2016 15:42 ET
|
Immune Design Corp.
SEATTLE and SOUTH SAN FRANCISCO, Calif., Jan. 08, 2016 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on oncology, today announced that the U.S....